Aerie Pharmaceuticals - AERI Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$15.25
+0 (0.00%)
Get New Aerie Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AERI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AERI

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Aerie Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $15.25.

This chart shows the closing price for AERI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Aerie Pharmaceuticals. This rating has held steady since August 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/17/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/17/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/29/2022CitigroupDowngradeBuy ➝ Neutral$14.00 ➝ $15.25
8/24/2022Truist FinancialDowngradeBuy ➝ Hold
8/24/2022HC WainwrightDowngradeBuy ➝ Neutral
8/23/2022Stifel NicolausDowngradeBuy ➝ Hold$15.00
8/23/2022Needham & Company LLCDowngradeBuy ➝ Hold
8/23/2022Cantor FitzgeraldDowngradeOverweight ➝ Neutral$30.00 ➝ $15.25
8/15/2022CitigroupBoost Target$14.00
8/9/2022CitigroupBoost Target$14.00
2/28/2022CitigroupLower Target$23.00 ➝ $13.00
2/25/2022CowenLower Target$30.00 ➝ $25.00
2/25/2022Needham & Company LLCLower TargetBuy$22.00 ➝ $14.00
12/17/2021Needham & Company LLCInitiated CoverageBuy$22.00
11/5/2021Needham & Company LLCLower TargetBuy$24.00 ➝ $22.00
9/17/2021Needham & Company LLCInitiated CoverageBuy$24.00
9/16/2021HC WainwrightReiterated RatingBuy$29.00
9/10/2021Needham & Company LLCInitiated CoverageBuy$24.00
8/27/2021Needham & Company LLCInitiated CoverageBuy$24.00
8/20/2021Needham & Company LLCInitiated CoverageBuy$24.00
8/5/2021Needham & Company LLCLower TargetBuy$26.00 ➝ $24.00
7/23/2021Needham & Company LLCInitiated CoverageBuy$26.00
7/22/2021MizuhoReiterated RatingBuy$28.00
7/16/2021Needham & Company LLCInitiated CoverageBuy$26.00
7/13/2021Raymond James FinancialSet Target$15.65
7/12/2021Raymond James FinancialReiterated RatingHold
7/9/2021Needham & Company LLCInitiated CoverageBuy$26.00
7/2/2021Needham & Company LLCInitiated CoverageBuy$26.00
4/30/2021Needham & Company LLCInitiated CoverageBuy$26.00
4/23/2021Needham & Company LLCInitiated CoverageBuy$26.00
3/1/2021HC WainwrightReiterated RatingBuy
2/5/2021Needham & Company LLCInitiated CoverageBuy$26.00
12/28/2020MizuhoReiterated RatingBuy$28.00
12/28/2020Needham & Company LLCReiterated RatingBuy$26.00
11/9/2020HC WainwrightLower TargetBuy$31.00 ➝ $29.00
11/6/2020MizuhoReiterated RatingBuy
10/19/2020Bank of AmericaDowngradeNeutral ➝ Underperform$14.00 ➝ $9.00
10/5/2020Raymond James FinancialReiterated RatingHold
10/5/2020Needham & Company LLCReiterated RatingBuy$26.00
9/28/2020Raymond James FinancialReiterated RatingHold
9/8/2020Raymond James FinancialReiterated RatingHold
9/8/2020GuggenheimInitiated CoverageBuy$20.00
8/24/2020Raymond James FinancialReiterated RatingHold
8/14/2020Needham & Company LLCInitiated CoverageBuy$26.00
8/10/2020CitigroupLower TargetBuy$38.00 ➝ $32.00
8/7/2020Piper SandlerLower Target$35.00 ➝ $25.00
8/7/2020MizuhoBoost TargetBuy$27.00 ➝ $29.00
8/7/2020Needham & Company LLCLower TargetBuy$32.00 ➝ $26.00
7/28/2020MizuhoReiterated RatingBuy$29.00
7/24/2020Needham & Company LLCInitiated CoverageBuy$32.00
(Data available from 7/18/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/17/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/19/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/18/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/18/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/17/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/17/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Aerie Pharmaceuticals logo
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $15.25
Low: $15.25
High: $15.25

50 Day Range

MA: $15.23
Low: $15.18
High: $15.25

52 Week Range

Now: $15.25
Low: $4.81
High: $15.37

Volume

600 shs

Average Volume

974,748 shs

Market Capitalization

$753.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Aerie Pharmaceuticals?

The following Wall Street analysts have issued research reports on Aerie Pharmaceuticals in the last twelve months: Wall Street Zen.
View the latest analyst ratings for AERI.

What is the current price target for Aerie Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Aerie Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Aerie Pharmaceuticals in the next year.
View the latest price targets for AERI.

What is the current consensus analyst rating for Aerie Pharmaceuticals?

Aerie Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AERI.

What other companies compete with Aerie Pharmaceuticals?

How do I contact Aerie Pharmaceuticals' investor relations team?

Aerie Pharmaceuticals' physical mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company's listed phone number is (919) 237-5300 and its investor relations email address is [email protected]. The official website for Aerie Pharmaceuticals is www.aeriepharma.com. Learn More about contacing Aerie Pharmaceuticals investor relations.